Thatch Raises $108M at a $1B Valuation — ICHRA Could Reshape the Revenue Cycle

Thatch has raised a $108 million Series C at a $1 billion valuation as employers increasingly shift from choosing one group health plan to giving employees defined healthcare budgets. The funding story is significant. For revenue cycle leaders, the more important question is what happens when employer-sponsored coverage begins to fragment into thousands of employee-selected individual plans — both before the claim and after something goes wrong.

The funding

Thatch announced a $108 million Series C with participation from The General Partnership, Index Ventures, Scale Venture Partners, General Catalyst, Andreessen Horowitz, Avid Ventures, Quiet Capital, SemperVirens and QuantumLight. Strategic investors include Eli Lilly and Company, ADP Ventures and Paychex.

The company says revenue has grown nearly 7x year over year and that it now powers health benefits for more than 5,000 employers. Thatch has also embedded distribution through payroll and HR platforms including Gusto, Justworks, Paychex and ADP.

The round gives Thatch a $1 billion valuation and more capital to expand carrier relationships, payroll integrations and the member experience around its core health-benefits model.

The model is different

Thatch's foundation is the Individual Coverage Health Reimbursement Arrangement, or ICHRA. Instead of an employer selecting a traditional group health plan, the employer establishes a defined contribution and employees use those dollars to purchase individual health insurance that fits their needs.

Thatch describes this as moving from health plans to health budgets. Employees can select individual coverage and, depending on plan design and eligibility, use remaining healthcare dollars for other qualified expenses.

For employers, the appeal is straightforward: more control over contribution levels and less exposure to the structure of a single group-plan renewal. For employees, the trade is greater choice and portability.

The RCM implication: more insurance variation at the front door

For providers, this shift can create a very different coverage mix. A workforce that once arrived under one or a handful of employer-sponsored group plans may increasingly arrive with individual policies selected by each employee.

That matters because revenue cycle performance depends heavily on knowing exactly what coverage is active, which network applies, what benefits remain and what the patient owes before care is delivered.

If ICHRA scales as its backers expect, front-end RCM teams may need to manage more plan variation even when the underlying patient population is still commercially insured.

• Eligibility becomes more dynamic. Providers cannot infer coverage from an employer relationship as reliably when employees select their own individual policies.
• Network status becomes more important. Individual-market products can have narrower or different networks than familiar employer group products, increasing the importance of accurate plan-level network identification.
• Benefit estimates get harder. More plan designs and carrier combinations increase the data required to produce reliable patient estimates before service.
• Patient responsibility may become less predictable. Deductibles, copays, coinsurance and plan structures can vary materially across employees who work for the same company.
• Registration errors become more expensive. The wrong payer, product or member information can cascade into denials and rework downstream.

There is another gap after the claim

The front-door complexity is only half the story. Quyra has highlighted a second-order ICHRA problem: the support model can become fragmented after a claim is adjudicated.

ICHRA administrators are primarily built to administer the benefit, facilitate plan selection and reimburse eligible expenses. But an employee can still encounter the familiar friction of health insurance after care: a denied claim, an unexpected out-of-network determination, an EOB that does not match the pre-service estimate, or a balance bill that arrives months later.

Under a traditional employer group plan, employees may have an HR or benefits team that helps escalate those problems through a broker or carrier relationship. As coverage becomes individualized, that institutional backstop can weaken. The employee owns the policy, but may not have the expertise to understand a denial reason, an appeal deadline, a network discrepancy or a coverage gap.

Why that matters to revenue cycle leaders

This is where the employer-benefits story intersects directly with provider RCM. When a patient does not understand why a claim denied or why a bill is larger than expected, the provider's call center and patient financial services team often become the de facto support layer — even when the root cause sits with the payer, the selected insurance product or the patient's network choice.

If ICHRA meaningfully expands the individual commercial market, providers should watch for several downstream effects:

• More patient billing questions. Patients new to individual-market coverage may need more help interpreting EOBs, deductibles, network status and balances.
• More fragmented denial navigation. Appeals and coverage disputes may vary by carrier, product and state, increasing the knowledge burden on both patients and provider staff.
• Greater estimate-to-EOB variance risk. Narrow networks and product-specific benefits make accurate pre-service financial communication more dependent on precise plan identification.
• A new opportunity for navigation infrastructure. Carrier-specific denial guidance, appeal workflows and post-claims support could become an important companion layer to ICHRA administration.

This does not mean ICHRA itself causes denials or surprise bills. Those problems already exist throughout commercial insurance. The structural issue is that moving plan choice from the employer to the individual can also redistribute who is responsible for navigating those problems when they occur.

ICHRA could accelerate the need for real-time eligibility intelligence

The operational response is not simply to add more verification staff. It is to make the front end more intelligent.

Revenue cycle platforms will need to identify the exact insurance product, validate active coverage, determine network participation and translate benefit data into an accurate financial expectation with less manual intervention.

This favors eligibility, patient-access and payer-data infrastructure that can normalize increasingly fragmented commercial coverage. It also raises the value of tools that can distinguish the carrier from the specific product and network rather than treating a payer name as sufficient.

There is a second-order payer implication

Thatch's thesis is that putting purchasing power closer to the consumer creates more competition among insurers and healthcare providers. If that happens at meaningful scale, the individual commercial market becomes more strategically important.

For health systems and physician groups, payer strategy may therefore need to extend beyond negotiating the largest employer-sponsored PPO contracts. Organizations will need better visibility into which individual-market products are growing locally, which networks they participate in, how those products reimburse and how often patients are arriving with them.

That creates a direct bridge between benefits innovation and payer intelligence.

Why the strategic investors matter

The investor list is worth watching. Paychex and ADP sit inside employer payroll and benefits workflows. Eli Lilly sits inside the healthcare spending ecosystem itself. Thatch is also distributing through Gusto and Justworks.

That distribution matters because ICHRA adoption does not have to happen employer by employer through a new standalone benefits channel. It can increasingly be presented inside systems businesses already use to run payroll and benefits.

If those embedded channels accelerate adoption, providers may experience the downstream insurance-mix change before many revenue cycle teams have explicitly planned for it.

The RCAI takeaway

Thatch's $108 million round is not an RCM funding event in the traditional sense. It may still have meaningful revenue cycle consequences.

The healthcare payment system has been built around relatively stable relationships among employers, group plans, payers and provider networks. ICHRA changes one of those assumptions by moving plan selection closer to the individual.

For RCM leaders, there are now two signals to watch. The first is at the front door: eligibility verification, network intelligence, patient estimates and payer-product identification become more important as commercial coverage becomes more individualized. The second is after adjudication: somebody still has to help patients navigate denials, appeals, network disputes and unexpected balances.

The companies that can connect those two sides — preventing avoidable coverage errors before the claim and helping resolve the inevitable friction after it — may capture an increasingly valuable layer of the revenue cycle.